| Literature DB >> 35684249 |
Mira Syahfriena Amir Rawa1,2, Mohd Khairul Nizam Mazlan1, Rosliza Ahmad1, Toshihiko Nogawa2,3, Habibah A Wahab1,2.
Abstract
Alzheimer's disease (AD) causes progressive memory loss and cognitive dysfunction. It is triggered by multifaceted burdens such as cholinergic toxicity, insulin resistance, neuroinflammation, and oxidative stress. Syzygium plants are ethnomedicinally used in treating inflammation, diabetes, as well as memory impairment. They are rich in antioxidant phenolic compounds, which can be multi-target neuroprotective agents against AD. This review attempts to review the pharmacological importance of the Syzygium genus in neuroprotection, focusing on anti-cholinesterase, anti-diabetic, anti-inflammatory, and antioxidant properties. Articles published in bibliographic databases within recent years relevant to neuroprotection were reviewed. About 10 species were examined for their anti-cholinesterase capacity. Most studies were conducted in the form of extracts rather than compounds. Syzygium aromaticum (particularly its essential oil and eugenol component) represents the most studied species owing to its economic significance in food and therapy. The molecular mechanisms of Syzygium species in neuroprotection include the inhibition of AChE to correct cholinergic transmission, suppression of pro-inflammatory mediators, oxidative stress markers, RIS production, enhancement of antioxidant enzymes, the restoration of brain ions homeostasis, the inhibition of microglial invasion, the modulation of ß-cell insulin release, the enhancement of lipid accumulation, glucose uptake, and adiponectin secretion via the activation of the insulin signaling pathway. Additional efforts are warranted to explore less studied species, including the Australian and Western Syzygium species. The effectiveness of the Syzygium genus in neuroprotective responses is markedly established, but further compound isolation, in silico, and clinical studies are demanded.Entities:
Keywords: Alzheimer’s disease; Syzygium; anti-cholinesterase; anti-diabetic; anti-inflammatory; antioxidant; medicinal plants; multi-target; neuroprotection
Year: 2022 PMID: 35684249 PMCID: PMC9183156 DOI: 10.3390/plants11111476
Source DB: PubMed Journal: Plants (Basel) ISSN: 2223-7747
Summary of anti-cholinesterase activities exerted from Syzygium species.
| Species | Plant Part/Compound | Test | Activity | Reference | |
|---|---|---|---|---|---|
| 1 | Ethanol leaf extract | In vitro AChE | 44.54 µg/mL of IC50 | [ | |
| Ex vivo AChE | No significant effect | ||||
| Leaf essential oil | In vitro AChE | 32.9 µg/mL of IC50 | [ | ||
| Polyphenol-rich leaf extract | In vitro AChE and BChE | Significant reduction in cholinesterase activities; bound polyphenolic extract showed better inhibitory activity than free polyphenolic extract | [ | ||
| Polyphenol-rich leaf extract | In vivo AChE and BChE from alloxan-induced diabetic rats | Enzyme activities were significantly reduced after 14 days (400 mg/kg oral dose) | [ | ||
| Methanol seed extract | In vivo AChE from scopolamine-induced rats | Significant reduction in AChE activity (400 mg/kg oral dose) | [ | ||
| Leaf extract | In vitro AChE | No significant activity | [ | ||
| 2 | Methanol leaf extract | In vitro ACHE and BChE | 16.04 µg/mL and 13.95 µg/mL of IC50, respectively | [ | |
| 3 | Methanol and ethyl acetate extracts from leaves | In vitro ACHE | 47.30 and 45.10 µg/mL of IC50, respectively | [ | |
| Methanol leaf and stem extracts | In vitro ACHE and BChE | >80% inhibition at 200 µg/mL concentration | [ | ||
| 4 | Methanol, ethyl acetate, and hexane extracts from leaves; methanol bud extract | In vitro ACHE | 42.10, 55.9, and 62.05 µg/mL of IC50, respectively (leaves); | [ | |
| Methanol extract, clove oil, and eugenol | In vitro ACHE and BChE using TLC bioautography | Eugenol (42.44 and 63.51 µg/mL of IC50) showed better inhibition than extract (61.5 and 103.53 µg/mL of IC50) and oil (49.73 and 88.14 µg/mL of IC50), respectively | [ | ||
| Clove bud essential oil | In vitro ACHE and BChE | 1.5 μL/L and 18.2 μL/L of IC50, respectively | [ | ||
| Ethanol extract | HPTLC-densitometry | Showed efficiency in AChE inhibition | [ | ||
| Ethanol bud extract | In vitro AChE isolated from human erythrocytes | No inhibitory effect | [ | ||
| Ethanol bud extract | In vitro AChE of parasite | 86.86% inhibition at 0.5 mg/mL after 8 hr exposure | [ | ||
| Clove oil (eugenol) encapsulated with a nanostructured lipid carrier | In vitro ACHE and BChE from | 4.3 and 3.5 mM of IC50, respectively | [ | ||
| Aqueous and hydroalcoholic extract of clove buds | In vitro AChE | 253.29 µg/mL of IC50 in aqueous extract | [ | ||
| Clove oil | In vitro AChE from AlCl3-induced rats | Significant reduction in AChE activity | [ | ||
| Ethanol bud extract | In vivo AChE from CeCI3-induced memory-impaired rats | Corrected the AChE rate caused by CeCI3 toxicity and improved cholinergic neural transmission | [ | ||
| Eugenol derivatives | In vitro ACHE and BChE | 4-Allyl-2-methoxyphenyl-4-ethyl benzoate inhibited AChE with 5.64 µg/mL of IC50 | [ | ||
| Isoeugenol | In vitro ACHE | 77 nM of IC50 | [ | ||
| 5 | Methanol leaf extract; ursolic acid; gallic acid | In vitro ACHE | 61.9% at 300 µg/mL concentration; 81.64% at 200 µg/mL concentration; 73.39% at 200 µg/mL concentration | [ | |
| 6 | Essential oil | In vitro ACHE and BChE | 4.83 and 5.69 mg GALAE/g, respectively | [ | |
| Dihydrochalcone | In vitro ACHE and BChE | 98.5% inhibition at 0.25 mM and 68% inhibition at 0.20 mM, respectively | [ | ||
| 7 | Essential oil | In vitro ACHE and BChE | 4.79 and 7.10 mg GALAE/g, respectively | [ | |
| 8 | Aqueous leaf extract | In vitro ACHE from homogenized tissue of rat brain | No significant activity | [ | |
| Methanol stem and leaf extracts | In vitro ACHE and BChE | >80% inhibition at 200 µg/mL concentration (16.05 and 15.25 µg/mL of IC50 from stem extract, respectively) | [ | ||
| 9 | Methanol leaf extract | In vitro ACHE and BChE | >80% inhibition at 200 µg/mL concentration | [ | |
| 10 | Methanol leaf extract | In vitro ACHE and BChE | >80% inhibition at 200 µg/mL concentration (20.69 µg/mL of IC50 for BChE) | [ |
Summary of anti-inflammatory activities reported from Syzygium species.
| Species | Plant Part/Compound | Test | Activity | Reference | |
|---|---|---|---|---|---|
| 1 | Methanol leaf extract | In vitro LPS-induced neuroinflammatory assay on murine BV-2 microglial cells; in vivo croton oil-induced ear edema test | Neuroprotective activity by a reduction in nitric oxide production in vitro; decreased mice ear edema in vivo | [ | |
| 2 |
| Methanol fruit extract | In vitro membrane stabilization, egg albumin denaturation, and bovine serum albumin denaturation assays; in vivo murine models of carrageenan, formaldehyde, and PGE2 induced paw edema. | Showed inflammatory activities both in vitro and in vivo | [ |
| Betulinic acid | In vivo Fx1A antiserum-induced passive Heymann nephritis (PHN) in Sprague-Dawley rats | Ameliorated mRNA and protein expression of NF-κB, iNOS, TNF-α, Nrf2, HO-1, and NQO1 in the kidney, reducing inflammation | [ | ||
| Polyphenol-rich leaf extract | In vivo Alloxan-induced diabetic rats | NF-κB and inflammatory cytokines such as TNF-α and IL-1α were regulated | [ | ||
| Anthocyanins di-glucosides from pulp | In vitro determination of cytokine production in LPS-induced RAW264.7 macrophages | Inhibited pro-inflammatory mediators such as IL-6, IL-1β, and TNF-α | [ | ||
| Aqueous seed extract | In vivo high cholesterol diet-streptozotocin-induced diabetes in rats | Exhibited significant anti-inflammatory and β-cell salvaging activity via overexpression of PPARγ and PPARα activity and a significant decrease in TNF-α levels when treated with 100, 200, 400 mg/kg/day doses | [ | ||
| Methanol seed extract | In vitro high glucose (HG) diabetic cardiomyopathy in | HG-induced activation of NF- | [ | ||
| Seed extract | In vivo Aβ1-40-infused AD model rats | Reduced the levels of Aß burdens and oligomers by suppressing the levels of TNFα and LPO in the corticohippocampal tissues | [ | ||
| 3 | Aqueous root extract | In vitro anti-inflammatory test using heat-induced albumin denaturation assay | 6.229 µg/mL of IC50 | [ | |
| 4 |
| Polyphenol-rich leaf extract | In vitro lipoxygenase inhibitor screening assay, membrane stabilizing activity (hypotonic solution-induced hemolysis), and in vivo carrageenan-induced hind-paw edema in rats | Inhibited LOX, COX-1, and COX-2 with higher COX-2 selectivity reduced the extent of lysis of erythrocytes and markedly reduced leukocyte numbers in rats challenged with carrageenan. | [ |
| Leaf extract | In vivo STZ-induced oxidative stress and inflammation in pancreatic beta cells in rats | Significantly decreased levels of TLR-4, MYD88, pro-inflammatory cytokines TNF-α, and TRAF-6 in pancreatic tissue homogenates, which correlated well with minimal pancreatic inflammatory cell infiltration | [ | ||
| 5 | Methanol bark extract | In vivo carrageenin- and egg albumin-induced paw edema, cotton pellet implanted granuloma in rats | Effective anti-inflammation at 200 mg/kg dose | [ | |
| 6 |
| Methanol bark extract | In vivo carrageenin- and egg albumin-induced paw edema, cotton pellet implanted granuloma | 200 mg/kg dose significantly reduced the paw edema in carrageenan (96.71%) and egg albumin models (54.24%) compared to the control. Chronic inflammation was also inhibited by up to 70.46% | [ |
| 7 |
| Ethanol/water extract | In vivo carrageenan-induced paw edema inflammatory in rats | Pretreatment at different doses (100, 200, and 400 mg/kg) produced a significant ( | [ |
| Essential oil | In vivo formalin-induced and carrageenan-induced paw edema inflammation in rats | 26.9 ± 2.5 μg/paw of EC50 | [ | ||
| Aqueous clove extract | In vivo LPS-induced lung inflammation in mice. | Inhibited matrix metalloproteinases: | [ | ||
| Ethanol extract | In vitro TNF-α induced inflammation in dental pulp stem cells | Prevented the increase in IL-6 levels | [ | ||
| Eugenol | Cytochrome c reduction assay to measure superoxide anion generation in human neutrophils | Inhibited the generation of superoxide anion by neutrophils via the inhibition of Raf/MEK/ERK1/2/p47phox-phosphorylation pathway | [ | ||
| Eugenol | In vivo ethanol-induced ulcer in rats | Decreased TNF-α and IL-6 cytokine concentrations responsible for inflammation | [ | ||
| Essential oil | Isbolographic study using the formalin test in rats | [ | |||
| 8 |
| Polyphenol vescalagin | In vivo methylglyoxal-induced inflammation in diabetic rats | The pancreatic levels of NF-κB, ICAM-1, and TNF-α protein, were reduced | [ |
| Lyophilized fruit powder | In vivo STZ-induced pancreatic beta cells apoptosis in rats | Pancreatic ß-cell apoptosis was alleviated with significantly down-regulated cleaved caspase-3 and Bax and upregulated Bcl-2 and Bcl-xl protein expression | [ | ||
| 9 |
| Leaf extract | In vivo coronary artery ligation-induced myocardial infarction in rats | Reduced levels of C-reactive protein (CRP) and myeloperoxidase (MPO) in the rats started from day 4 after the induction of myocardial infarction. | [ |
| 10 |
| Bark extract | In vivo streptozotocin-induced inflammation in diabetic rats | Significantly reduced TNF-α and increased IL-10 ( | [ |
Summary of plant parts or compounds examined for antioxidant activity from Syzygium species.
| Species | Plant Part/Compound | Reference | |
|---|---|---|---|
| 1 |
| Leaf | [ |
| Fruit | [ | ||
| Bark | [ | ||
| Polyphenol-rich extract | [ | ||
| Seed kernels powder | [ | ||
| 2 |
| Leaf | [ |
| 3 |
| Flower | [ |
| Bud | [ | ||
| Bud essential oil | [ | ||
| Eugenol | [ | ||
| All parts | [ | ||
| 4 |
| Leaf | [ |
| Gallic acid, myricitrin, and quercitrin | [ | ||
| 5 |
| Leaf | [ |
| Fruit | [ | ||
| Fruit pulp healthy snack | [ | ||
| 6 | Leaf | [ | |
| Fruit | [ | ||
| Volatile oil from the aerial part | [ | ||
| 7 |
| Leaf | [ |
| Myricetin derivatives | [ | ||
| 8 |
| Stem | [ |
| Bark | [ | ||
| 9 |
| Leaf | [ |
| 10 |
| Fruit | [ |
| Bark | [ | ||
| 11 |
| Vescalagin | [ |
| 12 | Leaf | [ |
Reported in vivo studies related to neuroprotection or aging from Syzygium species.
| Species | Plant Part/Compound | Test | Activity | Reference | |
|---|---|---|---|---|---|
| 1 |
| Seed extract | Eight-arm radial maze task for learning-related memory | Improved learning-related memory through the antioxidative defense by a reduction in corticohippocampal levels of lipid peroxide | [ |
| Seed extract | Aß1-40-infused AD model rats | Significantly increased the memory-related learning ability of the AD model rats with reductions in the levels of corticohippocampal Aβ1-40-burden and Aβ1-40-oligomers, and increased the levels of brain cognition and memory-related proteins, including BDNF, TrKB, PSD-95 and SNAP-25 | [ | ||
| 2 |
| Methanol leaves | POBCCA surgery in rats | Improved short- and long-term recognition memory in NOR test, improved spatial learning in MWM test at 200 mg/kg dose | [ |
| 3 |
| Aqueous bud extract | AlCl3-induced neurotoxic rats | Restored the parameters (Al, Ca2+, MDA, nitrite/nitrate, Mg+, Na+, GSH, GPx) to the near-normal levels, significantly normalized expression of the SOD1 gene | [ |
| Clove oil | Amyloid1-42-induced spatial memory-impaired rats | Improved spatial memory in Shuttle box test and apoptosis, PRDX6, and GCN5L1 levels were recovered through swimming training and clove consumption | [ | ||
| Clove oil | MCAO-stroke-induced rats | The pre-treated and post-treated groups with clove oil showed improvement in neurological deficit score | [ | ||
| Ethanol bud extract | CeCI3-induced memory-impaired mice | Symptoms of retracted neurons with condensed chromatin undergoing necrosis or apoptosis and vacuolated space were alleviated, which improved the state of memory in mice | [ | ||
| Clove essential oil | Extended lifespan and promoted production and health of | [ | |||
| 4 |
| Freeze-dried fruit | HFD-induced cognitive impaired rats | Improved AKT signaling in the hippocampus that prevented the activation of GSK3-β, lowered tau phosphorylation, and improved brain antioxidant enzyme activities. | [ |
Reported bioactive principles for neuroprotection from Syzygium species.
| Compound Name | Chemical Structure | Biological Activity | Reference | |
|---|---|---|---|---|
| 1 | Betulinic acid |
| Anti-inflammatory and antioxidant | [ |
| 2 | Eugenol |
| Anti-cholinesterase, anti-inflammatory, and antioxidant | [ |
| 3 | Isoeugenol |
| Anti-cholinesterase, and anti-diabetic | [ |
| 4 | Vescalagin |
| Anti-inflammatory, antioxidant, and anti-diabetic | [ |
| 5 | 2′,4′-Dihydroxy-6′- methoxy-3′,5′-dimethyl-dihydrochalcone |
| Anti-cholinesterase | [ |
| 6 | Ursolic acid |
| Anti-cholinesterase | [ |
| 7 | Gallic acid |
| Anti-cholinesterase | [ |
| 8 | Myricitin |
| Antioxidant and anti-diabetic | [ |
| 9 | Quercitin |
| Antioxidant | [ |
| 10 | 6-Heptadeca-8 |
| Anti-cholinesterase | [ |
| 11 | 6-Heptadeca-9 |
| Anti-cholinesterase | [ |
| 12 | ( |
| Anti-cholinesterase and anti-diabetic | [ |
| 13 | ß-Pinene |
| Anti-cholinesterase and anti-diabetic | [ |
| 14 | ( |
| Anti-cholinesterase and anti-diabetic | [ |
DMSO: dimethyl sulfoxide; EtOH: ethanol; MeOH: methanol.